Manmeet Ahluwalia MD, FACP, MBA
Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, FloridaDr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.
Recent Contributions to PracticeUpdate:
- Larotrectinib for Patients With TRK Fusion-Positive CNS Tumors
- Marizomib Plus Chemoradiotherapy for Newly Diagnosed Glioblastoma
- Nivolumab Plus Standard- or Reduced-Dosed Bevacizumab for Recurrent Glioblastoma
- Adjuvant—Not Concurrent—Temozolomide Upped Overall Survival in 1p/19q Non–Co-Deleted Anaplastic Glioma: Commentary on the CATNON Trial
- Adjuvant and Concurrent Temozolomide for 1p/19q Non–Co-Deleted Anaplastic Glioma
- Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves OS in High-Risk Metastatic NSCLC
- RT, RT + TMZ, or TMZ for Newly Diagnosed 1p/19q Codeleted Oligodendroglioma
- Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients
- Updated 2020 NCCN Guidelines for CNS tumors
- Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma